Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
01
03
2021
accepted:
28
06
2021
pubmed:
6
8
2021
medline:
18
9
2021
entrez:
5
8
2021
Statut:
ppublish
Résumé
We evaluated the safety and efficacy of fully closed-loop insulin therapy compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis. In an open-label, multinational, two-center, randomized crossover trial, 26 adults with type 2 diabetes requiring dialysis (17 men, 9 women, average age 68 ± 11 years (mean ± s.d.), diabetes duration of 20 ± 10 years) underwent two 20-day periods of unrestricted living, comparing the Cambridge fully closed-loop system using faster insulin aspart ('closed-loop') with standard insulin therapy and a masked continuous glucose monitor ('control') in random order. The primary endpoint was time in target glucose range (5.6-10.0 mmol l
Identifiants
pubmed: 34349267
doi: 10.1038/s41591-021-01453-z
pii: 10.1038/s41591-021-01453-z
pmc: PMC8363503
doi:
Substances chimiques
Blood Glucose
0
Insulin
0
Banques de données
ClinicalTrials.gov
['NCT04025775']
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1471-1476Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
UK Renal Registry 22nd Annual Report (The Renal Association, 2020); http://renal.org/audit-research/annual-report
ERA-EDTA Registry Annual Report 2018 (European Renal Association–European Dialysis and Transplant Association, 2020); https://www.era-edta.org/en/registry/publications/annual-reports
Abe, M. & Kalantar-Zadeh, K. Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat. Rev. Nephrol. 11, 302–313 (2015).
doi: 10.1038/nrneph.2015.38
Copur, S. et al. Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. Acta Diabetol. 58, 81–91 (2021).
doi: 10.1007/s00592-020-01581-x
Hill, C. J. et al. Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis. Am. J. Kidney Dis. 63, 84–94 (2014).
doi: 10.1053/j.ajkd.2013.06.020
Management of Adults with Diabetes on the Haemodialysis Unit (Joint British Diabetes Societies (JBDS) for Inpatient Care Group, 2016); https://abcd.care/resource/management-adults-diabetes-haemodialysis-unit
Galindo, R. J., Beck, R. W., Scioscia, M. F., Umpierrez, G. E. & Tuttle, K. R. Glycemic monitoring and management in advanced chronic kidney disease. Endocr. Rev. 41, 756–774 (2020).
doi: 10.1210/endrev/bnaa017
Hovorka, R. Closed-loop insulin delivery: from bench to clinical practice. Nat. Rev. Endocrinol. 7, 385–395 (2011).
doi: 10.1038/nrendo.2011.32
Thabit, H. et al. Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. Lancet Diabetes Endocrinol. 5, 117–124 (2017).
doi: 10.1016/S2213-8587(16)30280-7
Bally, L. et al. Closed-loop insulin delivery for glycemic control in noncritical care. N. Engl. J. Med. 379, 547–556 (2018).
doi: 10.1056/NEJMoa1805233
Boughton, C. K. et al. Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 7, 368–377 (2019).
doi: 10.1016/S2213-8587(19)30061-0
Bally, L. et al. Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis. Kidney Int. 96, 593–596 (2019).
doi: 10.1016/j.kint.2019.03.006
Leelarathna, L. et al. Duration of hybrid closed-loop insulin therapy to achieve representative glycemic outcomes in adults with type 1 diabetes. Diabetes Care 43, e38–e39 (2020).
doi: 10.2337/dc19-2041
Herrero, P., Alalitei, A., Reddy, M., Georgiou, P. & Oliver, N. Robust determination of the optimal continuous glucose monitoring length of intervention to evaluate long-term glycaemic control. Diabetes Technol. Ther. 23, 314–319 (2021).
doi: 10.1089/dia.2020.0387
Kazempour-Ardebili, S. et al. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care 32, 1137–1142 (2009).
doi: 10.2337/dc08-1688
Jung, H. S. et al. Analysis of hemodialysis-associated hypoglycemia in patients with type 2 diabetes using a continuous glucose monitoring system. Diabetes Technol. Ther. 12, 801–807 (2010).
doi: 10.1089/dia.2010.0067
Chu, Y. W. et al. Epidemiology and outcomes of hypoglycemia in patients with advanced diabetic kidney disease on dialysis: a national cohort study. PLoS ONE 12, e0174601 (2017).
doi: 10.1371/journal.pone.0174601
Polonsky, W. H., Fisher, L., Hessler, D. & Edelman, S. V. Investigating hypoglycemic confidence in type 1 and type 2 diabetes. Diabetes Technol. Ther. 19, 131–136 (2017).
doi: 10.1089/dia.2016.0366
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G. & Butterfield, J. Fear of hypoglycemia: quantification, validation and utilization. Diabetes Care 10, 617–621 (1987).
doi: 10.2337/diacare.10.5.617
Polonsky, W. H. et al. Assessment of diabetes-related distress. Diabetes Care 18, 754–760 (1995).
doi: 10.2337/diacare.18.6.754
Battelino, T. et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42, 1593–1603 (2019).
doi: 10.2337/dci19-0028
American Diabetes Association. 6. Glycemic targets. Standards of medical care in diabetes—2021. Diabetes Care 44, S73–S84 (2021).
doi: 10.2337/dc21-S006
Frankel, A. H. et al. Management of adults with diabetes on the haemodialysis unit: summary of guidance from the Joint British Diabetes Societies and the Renal Association. Diabet. Med. 35, 1018–1026 (2018).
doi: 10.1111/dme.13676
Jones, B. & Kenwood, M. G. Design and Analysis of Cross-Over Trials 3rd edn. (CRC Press, 2014).